Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Chloroquine Diphosphate: Autophagy Modulation in Cancer Rese
2026-06-15
Leverage Chloroquine Diphosphate as both an autophagy modulator and TLR7/TLR9 inhibitor to enhance chemotherapy and radiotherapy sensitivity in tumor models. This article provides actionable protocols, troubleshooting guidance, and a synthesis of emerging insights from ferroptosis-focused leukemia studies to empower translational oncology workflows.
-
Ivermectin in Parasitology Drug Development: Protocols and I
2026-06-15
Harness Ivermectin's broad-spectrum anti-parasitic action for rigorous parasitology research and translational drug development. This article details advanced workflows, troubleshooting strategies, and leverages recent tumor biology insights for assay innovation.
-
CUDC-907: Technical Guide for Dual PI3K and HDAC Inhibition
2026-06-14
CUDC-907 provides a dual PI3K and HDAC inhibitor for in vitro research, enabling simultaneous modulation of PI3K/AKT signaling and histone deacetylase activity in cancer models. It is not validated for diagnostic, therapeutic, or clinical use, and should be restricted to controlled laboratory workflows.
-
DiscoveryProbe FDA-approved Drug Library: HTS Workflow & Ins
2026-06-13
The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) empowers rapid, reproducible high-throughput screening and drug repositioning by providing 2,320 pre-dissolved, clinically validated compounds. This article details experimental workflows, troubleshooting, and real-world applications, including breakthroughs in thyroid eye disease target discovery.
-
Uridine, Trisodium Salt: Precision in RNA Biosynthesis Workf
2026-06-12
Uridine, Trisodium Salt unlocks scalable, high-fidelity RNA biosynthesis and site-specific genome engineering for modern molecular biology research. This article translates recent breakthroughs—including PRINT—into actionable protocols, comparative workflow tips, and troubleshooting strategies for maximizing yield and reproducibility.
-
Rucaparib (AG-014699): Optimizing DNA Damage Response Resear
2026-06-12
Rucaparib (AG-014699) stands out as a potent PARP1 inhibitor for translational cancer biology research, enabling precise interrogation of DNA repair pathways and radiosensitization. This guide details applied workflows, troubleshooting tactics, and insightful integration of recent discoveries in regulated cell death for robust DNA damage response studies.
-
CDK4 Regulates 4E-BP1 to Control Cap-Dependent Translation i
2026-06-11
This study uncovers a novel regulatory role for Cyclin-Dependent Kinase 4 (CDK4) in directly phosphorylating the translational repressor 4E-BP1, promoting cap-dependent translation during the mitosis–G1 transition. These findings expand our understanding of cell cycle control and translation regulation, with mechanistic implications for cancer biology and potential therapeutic strategies.
-
Saikosaponins Block Hedgehog Pathway in Medulloblastoma Mode
2026-06-11
This study demonstrates that Saikosaponin B1 and D, bioactive compounds from Bupleurum chinense, suppress medulloblastoma growth by inhibiting the Hedgehog signaling pathway at the Smoothened receptor. The findings clarify their mechanism of action and provide a platform to refine Hedgehog pathway assays in cancer and developmental biology research.
-
Small-Molecule Inhibition of uPAR–uPA Blocks Breast Cancer M
2026-06-10
This study demonstrates that IPR-803, a competitive urokinase receptor inhibitor identified via structure-based virtual screening, potently disrupts the uPAR–uPA interaction central to tumor invasion and metastasis. The compound’s biochemical, cellular, and in vivo efficacy in breast cancer models highlights its potential as a template for next-generation metastasis inhibitors.
-
A1 Astrocytes Drive M1 Microglia via p38 MAPK in Neuroinflam
2026-06-10
This study uncovers how 2-chloroethanol triggers A1 astrocyte activation via the p38 MAPK pathway, leading to M1 microglia polarization through cytokine signaling. The findings clarify the sequence and mechanisms underlying glial crosstalk in neuroinflammation, with implications for targeted intervention in toxic encephalopathy.
-
Crizotinib Hydrochloride: ALK Kinase Inhibitor in Assembloid
2026-06-09
Crizotinib hydrochloride empowers advanced cancer biology research by enabling precise inhibition of ALK, c-Met, and ROS1 in physiologically relevant assembloid models. This article delivers actionable workflows, performance insights, and troubleshooting strategies for leveraging this kinase inhibitor within next-generation tumor microenvironment studies.
-
Acifran’s Structural Insights: Precision Tools for Lipid Pat
2026-06-09
Explore how Acifran, a selective HM74A/GPR109A and GPR109B agonist, enables next-generation lipid metabolism and signaling pathway research. This article uniquely unpacks recent structural breakthroughs and practical protocol refinements for advanced assay design.
-
DiscoveryProbe FDA-approved Drug Library: Evidence & Applica
2026-06-08
The DiscoveryProbe FDA-approved Drug Library (SKU: L1021) enables high-throughput screening with 2,320 clinically approved compounds. This FDA-approved bioactive compound library accelerates drug repositioning and robust pharmacological target identification in cancer and neurodegenerative disease research.
-
LGK-974 (PORCN Inhibitor): Next-Generation Tool for Wnt-Driv
2026-06-08
Explore the scientific and translational significance of LGK-974, a potent PORCN inhibitor, for dissecting the Wnt signaling pathway in Wnt-driven cancer models. This article uniquely integrates recent mechanistic insights and rigorous protocol guidance for advanced pancreatic cancer research.
-
Nadolol (SQ-11725): Pharmacokinetic Control in Preclinical M
2026-06-07
Explore how Nadolol (SQ-11725) advances hypertension research and vascular headache studies by integrating transporter biology and pharmacokinetic insights. This article uniquely bridges tissue distribution mechanisms and assay design for reliable, reproducible results.